Participants sought: Effectiveness of ondansetron to reduce positive, negative and cognitive symptoms in schizophrenia

Molecule of interest affects neurotrans-
mitter serotonin. Image: Wikipedia

Monash Alfred Psychiatry Research Centre (MAPrc) is seeking volunteers diagnosed with schizophrenia to participate in a new study looking at the effectiveness of Ondansetron in reducing positive, negative and cognitive symptoms of schizophrenia.

What does our research involve?

• 12 week trial consisting of 5 study visits
• Two participant groups – patients taking clozapine and patients taking other atypical antipsychotic
• Participants in each group will be randomised to receive either ondansetron or placebo.

Participants sought: Investigating Ondansetron for chronic residual schizophrenia

The purpose of this study is to investigate the use of the medication Ondansetron as an adjunctive or add-on therapy to existing anti-psychotic medication in the treatment of schizophrenia symptoms. Ondansetron is a well established medication which is approved in Australia for the treatment of drug-induced nausea and vomiting. However, various case studies and clinical studies have shown Ondansetron to also be effective in the treatment of symptoms associated with persistent schizophrenia.